Unbiased Analysis of Today's Healthcare Issues
That is a key question if long-run drug prices are going to come down for biologic products. We can decompose this question into 3 sub-questions: What share patients initiating therapy start on a biosimilar? What share of patients already using a biologic products switch to a biosimilar? Do patient of physician factors drive biosimilar prescribing…
That is the question that the Outcome Measures in Rheumatology (OMERACT) Working Group attempted to answer. Specifically, the working group aimed to determine the core set of outcome domains for measuring the effectiveness of shared decision-making (SDM) interventions within clinical trials used to treat rheumatic diseases. These diseases included osteoarthritis (OA), rheumatoid arthritis (RA), and psoriatic…